CellCentric Closes Latest Funding Round With $220M In Tow
Clinical-stage biotechnology company CellCentric on Wednesday revealed that it closed its oversubscribed Series D financing round after securing $220 million from investors....To view the full article, register now.
Already a subscriber? Click here to view full article